Weed (BUDZ) Other Accumulated Expenses (2019 - 2020)
Weed (BUDZ) posted quarterly Other Accumulated Expenses of $18500.0 for Q4 2020, up 85.0% year-over-year from $10000.0 in Q1 2020, and up 85.0% quarter-over-quarter from $10000.0 in Q4 2019.
Weed (BUDZ) Other Accumulated Expenses (2019 - 2020) Analysis & Trends
Weed's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $18500.0 for Q4 2020.
- In Q4 2020, Other Accumulated Expenses rose 85.0% year-over-year to $18500.0; the TTM figure through Dec 2020 stood at $18500.0 (up 85.0% YoY), while the FY2020 annual figure was $18500.0, up 85.0% from the prior year.
- Other Accumulated Expenses for Q4 2020 stood at $18500.0, up from $10000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $18500.0 in Q4 2020, with the low at $10000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Weed | 3.13 Mn | 3.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 18,500.00 |
| Dec 31, 2019 | 10,000.00 |